NEW YORK (GenomeWeb News) – Cepheid this week updated its test pipeline with a focus on gonorrhea and chlamydia, cancer, and tuberculosis over the next few years.

Speaking at two investor conferences, Cepheid CEO John Bishop outlined his company's plans to expand its testing menu through 2017, when if all goes according to plans, the company would have a total of 42 tests available globally.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.